Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clazakizumab for COVID-19 in patients with kidney disease
2020-002476-13Phase 2Unknown
- Sponsor
- Imperial College London
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of clazakizumab in coronavirus disease 2019 (COVID-19) and chronic kidney disease (CKD), sponsored by Imperial College London. Primary endpoint: Hospital discharge by day 28. Status: unknown.
02
Drugs
clazakizumab
03
Conditions
coronavirus disease 2019 (COVID-19)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2020-002476-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002476-13.